Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Establishes $400M Loan Facility for Caliper Purchase

NEW YORK (GenomeWeb News) – PerkinElmer has entered into a commitment letter for a 364-day bridge loan facility for up to $400 million to fund its proposed purchase of Caliper Life Sciences, it disclosed this week in a document filed with the US Securities and Exchange Commission.

The firm said it entered into a commitment letter on Sept. 7 with Bank of America and Merrill Lynch, Pierce, Fenner & Smith for the loan facility. Bank of America will act as an initial lender and administrative agent, while Merrill Lynch will be the lead arranger and book-running manager.

In addition to helping fund PerkinElmer's $600 million proposed acquisition of Caliper, the loan facility will be used to refinance certain of both firms' debt, and to pay fees and expenses incurred in connection with the transactions.

In connection with the loan facility, PerkinElmer has agreed to engage an investment banker and "use commercially reasonable efforts" to issue up to $400 million of senior unsecured notes or other securities.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.